A new case study out of New York University’s Steinhardt School of Culture, Education, and Human Development suggests that face transplant surgery in patients who have experienced severe facial trauma can improve speech production.
“Our findings provide a window into the complex recovery process following major facial reconstruction and serve as an important foundation from which we can begin to understand how facial transplant can improve speech production preoperatively to postoperatively,” said Maria I. Grigos, the study’s lead author and associate professor of communicative sciences and disorders at NYU Steinhardt.
“Among the many remarkable patterns observed, we found that the patient displayed more flexible control of facial movement as he adapted to the transplanted structures.”
RealSelf unveiled the 2019 Worth It Ranking, a comprehensive list that ranks the Worth It Ratings of more than 140 surgical and nonsurgical cosmetic procedures and brands.
The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as “Worth It” or “Not Worth It.”
In addition to the full ranking, RealSelf announced the treatments designated as the “Most Worth It” procedures for 2019. The top-ranked surgical procedure was breast implant removal with a 99% Worth It Rating, while diVa Vaginal Therapy, a laser used to address changes in vaginal health often caused by childbirth and menopause, ranked highest for nonsurgical treatments with a 100% Worth It Rating.
The natural scar-free skin repair process relies partially on assistance from circulating blood cells. Results from a study published recently in Nature Communications point the way toward possible treatments for scar-free wound healing that target the body’s own blood cells.
Maksim Plikus, an associate professor in developmental and cell biology at the UCI School of Biological Sciences, and colleagues, led the study, along with George Cotsarelis from University of Pennsylvania.
Skin injuries activate rapid wound repair, which often culminates with the formation of scars. Unlike normal skin, scars are devoid of hair follicles and fat cells, and creating new hair and fat is necessary for regenerating an equivalent of normal skin. In a 2017 paper published in Science, Plikus and colleagues identified that adult mice can naturally regenerate nearly normal-looking skin when new hair follicles and fat cells form in healing wounds.
New fat cells regenerate from myofibroblasts, a type of wound fibroblast that was previously not thought to be capable of converting into other cell types. This discovery brought renewed attention to wound fibroblasts as attractive targets for anti-scarring therapies.
In the recent study, the research team sought to further characterize wound fibroblasts and determine if they’re all the same and equally capable of regenerating new fat cells.
Using a panel of single-cell tools as a type of “computational microscope” that examines thousands of individual cells at once, the research team observed an unexpectedly high degree of fibroblast diversity.
“We saw that wound fibroblasts are surprisingly very diverse and that there are as many as twelve different cell sub-types. We understand their molecular signatures and are beginning to learn about their unique biology. For example, we already know that distinct fibroblast sub-types ‘prefer’ only certain parts of the wound. This suggests that they play specific roles in different locations within the wound, and possibly at different times during the repair process,” said Christian Guerrero-Juarez, a postdoctoral fellow at UCI and first author on the project, in a media release from Newswise.
After a closer look at wound fibroblasts, the team noted that a sizable group of cells had the molecular telltale signs of having originated from blood.
“Molecular profiling of wound fibroblasts strongly suggests that as many as 13% of them at some point in their past were blood cells that converted into collagen-producing fibroblasts, but kept residual blood-specific genes still turned on,” said Plikus.
Indeed, blood cell-derived fibroblasts have been reported by others in the past, including located in wound scars. “What is truly novel about our observation is that these fibroblast-making blood cells, which are called myeloid cells, can reprogram into new fat cells,” Plikus said. “In essence, we observed that for wounds to achieve scar-less regeneration, the body must mobilize multiple cellular resources, which includes remotely circulating blood progenitors.”
Because myeloid cells can be fairly easy to harvest and enrich using existing techniques, the new findings open the exciting possibility that the skin’s healing ability can be enhanced via delivery of regeneration-competent blood-derived progenitors to the site of the wound. As an immediate next step, an information-rich catalog of diverse wound fibroblasts will help form a platform for the team to begin identifying new sub-types of cells that enhance scarring, or promote repair toward scar-less skin regeneration.
[Source(s): University of California Irvine, Newswise]
What is the monetary value of changes in attractiveness achieved through rhinoplasty, as perceived by society? Researchers posed this question in a study published recently in JAMA Plastic Surgery.
To aid them in answering this question, Researchers performed a cross-sectional survey administered via public online forums to 228 casual observers.
Survey results suggest that there is an association, according to the researchers.
For one standard deviation increase in attractiveness, a rhinoplasty was valued at $6123.75, and for two standard deviations increase in attractiveness, it was valued at $9223.05.
Findings thus suggest contingent valuation, or willingness to pay, to be a well-established economic concept that could be used for the valuation of cosmetic facial procedures.
[Source: MDLinx Otolaryngology]
Combination surgical excision/laser treatment shows better clinical outcomes and patient satisfaction, according to a study published recently in Lasers in Surgery and Medicine, the official journal of the American Society for Laser Medicine and Surgery Inc (ASLMS).
Congenital melanocytic nevi (CMN) are nevi (birthmarks) that present at birth or arise within the first few weeks of life. For small to medium sized CMN, the current treatment of choice is staged surgical excision. Ablative lasers or pigment-specific lasers have also been recommended for lesions difficult for surgical removal or to avoid surgery.
In this study, researchers led by Jung Min Lim, MD, retrospectively analyzed the results of several treatment options for CMN to determine the optimal treatment method, according to a media release from ASLMS.
A total of 119 cases with small to medium sized CMN were retrospectively reviewed. Treatment options were categorized into four groups: (i) Excision only; (ii) Excision followed by scar laser; (iii) Excision followed by pigment specific laser; and (iv) Laser only.
For the treatment of small to medium sized CMN, treatment strategies including surgical methods are cosmetically superior to laser-only treatment. Also, the combination of surgical excision with scar laser has the potential for better clinical outcomes and patient satisfaction, per the release..
“This large-scale retrospective review about treatment options for small to medium congenital melanocytic nevi may give reassurance to clinicians seeking the best option for their patient, as large-scale assessments have never been made in this field,” says Lim, from the Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
“It strongly supports the efficacy of surgical excision, which showed better cosmetic outcomes, while suggesting the need for improvement in laser-based treatment strategies. This review also promises the potential of combining scar lasers with surgical excision, which showed superior outcomes along with increased patient satisfaction.
“As various tools for treatment are constantly being developed, the comparison of different treatment strategies in a large scale will benefit the clinician in their daily practice,” Lim concludes, in the release.
[Source: American Society for Laser Medicine and Surgery Inc]
Treating psoriasis, a chronic inflammatory skin disease, with biologic drugs that target immune system activity can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, researchers suggest.
The findings highlight how immunotherapies that treat inflammatory conditions might play a role in the reduction of cardiovascular disease risks. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, appears online in the journal Cardiovascular Research.
“Classically a heart attack is caused by one of five risk factors: diabetes, hypertension, high cholesterol, family history, or smoking,” says Nehal N. Mehta, MD, head of the Lab of Inflammation and Cardiometabolic Diseases at NHLBI, in a media release from National Institutes of Health.
“Our study presents evidence that there is a sixth factor, inflammation; and that it is critical to both the development and the progression of atherosclerosis to heart attack.”
Now researchers provided first in-human evidence that treatment of a known inflammatory condition with biologic therapy, a type of drugs that suppresses the immune system, was associated with a reduction in coronary artery disease, in particular of rupture prone plaque which often leads to a heart attack.
Psoriasis, a common skin disease affecting 3-5 percent of the U.S. population, is associated with heightened systemic inflammation, which elevates risk of blood vessel disease and diabetes. Inflammation occurs when the body’s defensive mechanism kicks in to ward off infection or disease, but this mechanism can turn against itself when triggered, for instance, by excess low-density lipoproteins (LDLs) that seep into the lining of the arteries.
The resulting inflammatory response can cause blood clots, which block arteries and can lead to heart attack and stroke. Inflammation puts 20-30 percent of the U.S. population at risk for these kinds of events. People with inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis have a much higher rate of cardiovascular events.
Those high rates make worse already troubling numbers: More than 15 million Americans, and many more worldwide, suffer from atherosclerotic cardiovascular disease. Heart attack occurs in 750,000 individuals every year in the United States; globally, more than 7 million people had heart attacks in 2015.
The current findings came from an observational study of the NIH Psoriasis Atherosclerosis Cardiometabolic Initiative cohort, which had 290 psoriasis patients, 121 of whom suffered moderate to severe skin disease and qualified for the biologic therapy approved by the U.S. Food and Drug Administration, the release explains.
For a year, researchers followed the eligible patients, all of whom had low cardiovascular risk, and compared them to those who elected not to receive biologic therapy. Study results show that biologic therapy was associated with an 8 percent reduction in coronary artery plaque.
“The findings that intrigued us most were that coronary plaque sub-components changed over one year, including the necrotic core and non-calcified components, which are the culprits for most heart attacks,” Mehta said.
Prior research had linked psoriasis with premature development of high-risk coronary plaque. Now, Mehta’s team has shown beneficial changes in this plaque when psoriasis is treated with biologic therapy – even without changes in other cardiovascular risk factors such as cholesterol, glucose, and blood pressure.
“This appears to be an anti-inflammatory effect. In the absence of improvement in other cardiovascular risk factors, and without adding new cholesterol medications, patients’ soft-plaque still improved. The only change was the severity of their skin disease,” said Mehta.
Researchers say continued research will need to be done to confirm whether this is so, or whether the positive effect is a result of treating the underlying inflammatory disease.
“Our data are observational so the next steps should be randomized, controlled trials,” Mehta concludes.
[Source: National Institutes of Health]
An intraoral mandibular contour surgery (MCS) training system is effective for improving clinical surgery time and accuracy, according to a study published recently in JAMA Facial Plastic Surgery.
Jia Qiao, M.D., from the Chinese Academy of Medical Sciences in Beijing, and colleagues enrolled 90 consecutive MCS patients and 15 craniofacial surgery fellow physicians (five per group) in a prospective observational study. Participants were randomly assigned to either an intervention group (groups A and B) or a control group (group C).
The intervention groups completed five training sessions on the intraoral MCS training models, constructed by three-dimensional skull models covered with elastic head cloths, before each clinical case. Intraoral MCS training models were provided to groups A and B; group A also had surgical templates provided in training sessions and clinical surgeries.
The researchers found that all patients were satisfied with their postoperative mandible contours. Groups A and B had improvement in clinical surgery time (mean, 147.2, 184.47, and 219.3 minutes for groups A, B, and C, respectively) and surgical accuracy (mean, 0.68, 1.22, and 1.88 mm, respectively), with greater improvements in group A. Improvements were also noted in learning curves and operators’ confidence and surgical skill.
“The overriding goal of this project was to establish a better way to achieve optimal results in training plastic surgery resident physicians and fellow physicians,” the authors write. “It is simple, economical, and can significantly improve the training quality of surgical trainees.”
[Source: MedicalXPress, HealthDay]
Getting a mammogram before breast reduction surgery is not required or recommended. But thousands of younger women with no known breast cancer risk still get them, a new study suggests.
Although the pre-surgical screening has been a longtime practice among physicians, no professional society recommends routine screening until a woman turns 40.
Erika D. Sears, MD, MS, a Michigan Medicine plastic surgeon who studies appropriateness and efficiency in health care, wondered how often the practice takes place.
Her new study, published in JAMA Surgery, found that nearly one-third of women younger than 40 underwent mammography before breast reduction surgery. Health services researchers culled the records of 52,486 women of all ages being evaluated for breast reduction between 2009 and 2015.
Few may realize the unnecessary screenings come at a price — and not just a monetary one that adds to the nation’s health care bill, Sears says.
“Altering screening mammography for patients younger than 40 years in the setting of evaluation for breast surgery has a risk for subsequent tests and invasive procedures,” says Sears, also an assistant professor of surgery at the University of Michigan.
The study showed 30 percent of women ages 30 to 39 had mammograms before breast reduction surgery, a rate five times higher than that of other women their age.
About 4 percent of women ages 29 and younger received mammograms as they considered breast reduction — compared with 0.2 percent of the population of millennial women.
When performing the analysis, researchers had excluded women whose medical records indicated a personal or family history of breast cancer, genetic predisposition or prior benign breast disease — although there’s a chance the risk existed but wasn’t noted in their records, explains a media release from Michigan Medicine – University of Michigan.
Among the women in their 30s who had mammograms before breast reduction surgery, 14 percent went on to have an MRI, ultrasonography, or a biopsy in which breast tissue or fluid is removed for laboratory testing.
Cancer was found in only 0.5 percent of the women, the study showed.
That finding could help shift the conversation on both sides.
“I think that if there’s more awareness among patients, they may be motivated to have a conversation with their doctor about whether screening mammography is right for them,” Sears says. “It’s also about education on the provider’s part about the downstream impact of future testing that women may experience.”
[Source(s): Michigan Medicine – University of Michigan, Science Daily]
Melanoma is the deadliest form of skin cancer and notorious for its resistance to conventional chemotherapy. Approximately 25 percent of melanoma is driven by oncogenic mutations in the NRAS gene, making it a very attractive therapeutic target. However, despite decades of research, no effective therapies targeting NRAS have been forthcoming.
Reportedly for the first time, an international group of researchers has discovered a novel activator of NRAS and developed a specific inhibitor to effectively prevent NRAS mutant melanoma growth. These findings provide a promising therapeutic option to treat NRAS mutant melanoma.
These findings appear in the journal CELL, according to a media release from Boston University School of Medicine.
The researchers first identified STK19 (an enzyme encoded by the STK19 gene) to be a critical regulator of NRAS function. Then they characterized the mechanism by which this activation takes place through biochemical and cellular experiments. Finally, they designed an STK19 inhibitor that efficiently prevented NRAS activation and development of NRAS mutant melanoma in an experimental model.
“This study provides a promising therapeutic strategy for melanoma treatment. Furthermore, the STK19 inhibitor might be a therapeutic option in 25 percent of all cancers with RAS mutations,” explained corresponding author Rutao Cui, MD, PhD, professor of pharmacology & experimental therapeutics at Boston University School of Medicine. “We hope our findings ultimately will be clinically translated into improved care for cancer patients.”
[Source(s): Boston University School of Medicine, EurekAlert]
Syneron Medical Ltd and Candela Corporation, and Lutronic Corp and Lutronic Aesthetics Inc, announce that they have entered into a mutually agreeable comprehensive settlement agreement ending the patent disputes between the companies.
Terms of the settlement agreement were not disclosed.
The mutually agreed-upon settlement, limited to Lutronic, protects Candela’s investment in Profound and its patented long pulse and temperature-controlled technology today and in the future. The settlement, through a sublicense from Syneron-Candela, allows Lutronic to market its product in the short pulse category, protecting Candela’s investment in the development of products in the long pulse category with a thermocouple.
For more information, read the full news release at www.prnewswire.com